Predictors of Nonsentinel Lymph Node Positivity in Patients with a Positive Sentinel Node for Melanoma
- 31 July 2005
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 201 (1) , 37-47
- https://doi.org/10.1016/j.jamcollsurg.2005.03.029
Abstract
Patients found to harbor melanoma micrometastases in the sentinel lymph node (SLN) are recommended to proceed to complete lymph node dissection (CLND), although the majority of patients will have no additional disease identified in the nonsentinel lymph nodes (NSLNs). We sought to assess predictive factors associated with finding positive NSLNs, and identify a subset of patients with low likelihood of finding additional disease on CLND. We queried our prospective melanoma database for patients from January 1996 to August 2003 with a positive SLN. Univariable logistic regression models were fit for multiple factors and a positive NSLN. To derive a probabilistic model for occurrence of one or more positive NSLN(s), a multivariable logistic model was fit using a stepwise variable selection method. Of 980 patients who underwent SLN biopsy for cutaneous melanoma, 232 (24%) had a positive SLN; 221 (23%) followed by CLND. Of these patients, 34 (15%) had one or more positive NSLN(s). In multivariable analysis, male gender (odds ratio [OR] 3.6 [95% CI 1.33, 9.71]; p = 0.01), Breslow thickness (OR 4.58 [95% CI 1.28, 16.36]; p = 0.019), extranodal extension (OR 3.2 [95% CI 1.0, 10.5]; p = 0.05), and three or more positive sentinel nodes (OR 65.81 [95% CI 5.2, 825.7]; p = 0.001) were all associated with the likelihood of finding additional positive nodes on CLND. Of 47 patients with minimal tumor burden in the SLN, only 1 (2%) had additional disease in the NSLN. These results provide additional data to plan clinical trials to answer the question of who can safely avoid CLND after a positive SLN. Patients with minimal tumor burden in the SLN might be the most likely group, although defining "minimal tumor burden" must be standardized. Serial sectioning and immunohistochemistry on the NSLN in any "low-risk" group must be performed in a clinical trial to confirm that residual disease is unlikely before avoiding CLND can be recommended.Keywords
This publication has 28 references indexed in Scilit:
- Factors Predictive of Tumor-Positive Nonsentinel Lymph Nodes After Tumor-Positive Sentinel Lymph Node Dissection for MelanomaJournal of Clinical Oncology, 2004
- Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel nodeLaboratory Investigation, 2004
- Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful?Journal of the American Academy of Dermatology, 2004
- Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patientsCancer, 2003
- Clinical Outcome of Stage I/II Melanoma Patients After Selective Sentinel Lymph Node Dissection: Long-Term Follow-Up ResultsJournal of Clinical Oncology, 2003
- Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm)Annals of Surgical Oncology, 2000
- Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomyJournal of the American College of Surgeons, 1999
- Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trialThe Lancet, 1998
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Occult melanoma in lymph nodes detected by antiserum to S-100 proteinInternational Journal of Cancer, 1984